To assess the cardiovascular safety of antimuscarinic drugs to treat overactive bladder (OAB) in Denmark.

Trial Profile

To assess the cardiovascular safety of antimuscarinic drugs to treat overactive bladder (OAB) in Denmark.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Nov 2017

At a glance

  • Drugs Darifenacin (Primary) ; Fesoterodine (Primary) ; Oxybutynin (Primary) ; Solifenacin (Primary) ; Tolterodine (Primary) ; Trospium chloride (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Nov 2017 New trial record
    • 13 Nov 2017 Results assessing cardiovascular safety of antimuscarinic drugs to treat overactive bladder (OAB) in Denmark, were published in the European Journal of Clinical Pharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top